CLOZAPINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H19ClN4
Molecular Weight	326.823
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1CCN(CC1)C2=NC3=C(NC4=C2C=CC=C4)C=CC(Cl)=C3

InChI

InChIKey=QZUDBNBUXVUHMW-UHFFFAOYSA-N

InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

HIDE SMILES / InChI

Molecular Formula	C18H19ClN4
Molecular Weight	326.823
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical
Record UNII	J60AR2IKIC
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

CLOZAPINE

Official Name

English

CLOZAPINE [JAN]

Common Name

English

LEPONEX

Brand Name

English

8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

Systematic Name

English

CLOZAPINE [USP-RS]

Common Name

English

Showing 1 to 5 of 31 entries

Previous1 2 3 4 5 6 7Next

Show entries

Classification Tree

Code System

Code

Designated

FDA ORPHAN DRUG

357411

Agent Affecting Nervous System

NCI_THESAURUS

C29710

Antipsychotic

LIVERTOX

NBK548412

Established Pharmacologic Class

NDF-RT

N0000175430

Serotonin Antagonist

NCI_THESAURUS

C94726

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

DRUG CENTRAL

722

PRIMARY

IUPHAR

38

PRIMARY

EPA CompTox

DTXSID5022855

PRIMARY

JAPANESE REVIEW

CLOZARIL

PRIMARY

APPROVED APRIL 2009

MESH

D003024

PRIMARY

Showing 1 to 5 of 25 entries

Previous1 2 3 4 5Next

Show entries

Related Record

Type

Details


					LR0F81F33L

ALDEHYDE OXIDASE

METABOLIC ENZYME -> INHIBITOR

Qualification:

IC50

Amount:

4.4 MICROMOLAR [2.2 to 6.2] (average)


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:

94 % (average)


					NQI5D806LC

5-HYDROXYTRYPTAMINE RECEPTOR 2A

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

24 NANOMOLAR [21.9 to 27.1] (average)


					VK4SQL11C0

CYTOCHROME P450 1A2

METABOLIC ENZYME -> SUBSTRATE


					80862U56A3

CLOZAPINE HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					1I9001LWY8

NORCLOZAPINE

METABOLITE ACTIVE -> PARENT

Comments:

ACTIVITY OF NORCLOZAPINE AGAINST DOPAMINE AND SEROTONIN RECEPTOR MAY DIFFER FROM THAT OF CLOZAPINE

Interaction Type:

MAJOR

Amount:


					MZA8BK588J

CLOZAPINE N-OXIDE

METABOLITE LESS ACTIVE -> PARENT

Interaction Type:

MAJOR

Amount:


					MZA8BK588J

CLOZAPINE N-OXIDE

METABOLITE LESS ACTIVE -> PARENT

Comments:

APPEARS TO HAVE LESS ACTIVITY THAN CLOZAPINE AND NORCLOZAPINE AGAINST 5HT RECEPTORS

Interaction Type:

MAJOR

Amount:


					1I9001LWY8

NORCLOZAPINE

METABOLITE ACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

Significant Metabolite

Amount:

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					QT944N7MN3

8-CHLORO-5,10-DIHYDRO-11H-DIBENZO(B,E)(1,4)DIAZEPIN-11-ONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

CLINICALLY SIGNIFICANT

Amount:

[<0.1] PERCENT PEAK AREA (limits)


					AI23QM53UB

11,11-(PIPERAZINE-1,4-DIYL)BIS(8-CHLORO-5H-DIBENZO(B,E)(1,4)DIAZEPINE)

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

[<0.2] PERCENT PEAK AREA (limits)


					1I9001LWY8

NORCLOZAPINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

[<0.3] PERCENT PEAK AREA (limits)


					9G48ZX6Q5Y

(2-((2-AMINO-4-CHLOROPHENYL)AMINO)PHENYL)(4-METHYL-1-PIPERAZINYL)METHANONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

[<0.2] PERCENT PEAK AREA (limits)

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					J60AR2IKIC

CLOZAPINE

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC	8 hours (average)